You have read all your free articles, to continue reading subscribe to read the rest of this content.
SynAct Pharma has announced that an independent Data Safety Monitoring Board (DSMB) has reviewed unblinded and validated data from part 1 of the company’s Phase 2a study in patients with rheumatoid arthritis (RA) with high disease activity with the aim to recommend which dose(s) of AP1189 to be brAlready a…
Medivir announces the successful completion of the pre-clinical safety studies for MIV-818 to enable the start of phase I clinical trials in 2018. MIV-818 is Medivir's liver-targeted nucleotide prodrug for the treatment of hepatocellular carcinoma (HCC) and other forms of liver cancer. It is the Already a subscriber Login You…
ALK has announced that for the first time, allergy immunotherapy is now recommended as a treatment option in the Global Initiative for Asthma (GINA) report: Global Strategy for Asthma Management and Prevention. This global strategy is a practical resource developed to guide healthcare professionAlready a subscriber Login You have read all…
Nordic Nanovector provides an update on PARADIGME, its ongoing Phase 2b trial of Betalutin in 3rd-line relapsed/refractory follicular lymphoma. Despite COVID has the company seen a significant improvement in the enrolment rate from approximately two to approximately five patients per month, it stAlready a subscriber Login You have read all…
